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BSTRACT
 
Background
 
It is unclear whether primary prophy-
laxis against 
 
Pneumocystis carinii
 
 pneumonia can be
discontinued in patients infected with the human
immunodeficiency virus (HIV) who are successfully
treated with combination antiretroviral therapy. We
prospectively studied the safety of stopping prophy-
laxis among patients in the Swiss HIV Cohort Study.
 
Methods
 
Patients were eligible for our study if
their CD4 counts had increased to at least 200 cells
per cubic millimeter and 14 percent of total lympho-
cytes while they were receiving combination antiret-
roviral therapy, with these levels sustained for at
least 12 weeks. Prophylaxis was stopped at study en-
try, and patients were examined every three months
thereafter. The development of 
 
P. carinii
 
 pneumonia
was the primary end point, and the development of
toxoplasmic encephalitis the secondary end point.
 
Results
 
Of the 262 patients included in our analy-
sis, 121 (46.2 percent) were positive for IgG antibod-
ies to 
 
Toxoplasma gondii 
 
at base line
 
.
 
 The median
CD4 count at study entry was 325 per cubic millime-
ter (range, 210 to 806); the median nadir CD4 count
was 110 per cubic millimeter (range, 0 to 240). Dur-
ing a median follow-up of 11.3 months (range, 3.0 to
18.8), prophylaxis was resumed in nine patients, and
two patients died. There were no cases of 
 
P. carinii
 
pneumonia or toxoplasmic encephalitis. The one-
sided upper 99 percent confidence limit for the inci-
dence of 
 
P. carinii
 
 pneumonia was 1.9 cases per 100
patient-years (based on 238 patient-years of follow-
up). The corresponding figure for toxoplasmic en-
cephalitis was 4.2 per 100 patient-years (based on
110 patient-years of follow-up).
 
Conclusions
 
Stopping primary prophylaxis against
 
P. carinii
 
 pneumonia appears to be safe in HIV-infect-
ed patients who are receiving combination antiretro-
viral treatment and who have had a sustained in-
crease in their CD4 counts to at least 200 cells per
cubic millimeter and to at least 14 percent of total
lymphocytes. (N Engl J Med 1999;340:1301-6.)
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OR many years 
 
Pneumocystis carinii 
 
pneu-
monia has been the most frequent event de-
fining the presence of the acquired immuno-
deficiency syndrome (AIDS) among adults
in developed countries who are infected with the
human immunodeficiency virus (HIV).
 
1,2
 
 
 
P. carinii
 
pneumonia is associated with considerable morbidi-
ty and mortality
 
3,4
 
; it occurs predominantly in pa-
tients in whom the number of CD4-positive lym-
phocytes has fallen below 200 per cubic millimeter,
with an estimated incidence of 20 cases per 100 pa-
tient-years.
 
5,6
 
 Several studies have shown that pri-
mary prophylaxis with trimethoprim–sulfamethox-
azole,
 
7
 
 inhaled pentamidine,
 
6
 
 or dapsone, with or
without pyrimethamine, substantially reduces the in-
cidence of 
 
P. carinii 
 
pneumonia
 
.
 
8,9
 
 Patients with a pos-
itive serum test for IgG antibodies to 
 
Toxoplasma
gondii
 
 are also at risk for toxoplasmic encephalitis,
the incidence of which is about 12 percent at one year
among patients whose CD4 counts have fallen below
200 per cubic millimeter.
 
10
 
 Trimethoprim–sulfameth-
oxazole and dapsone plus pyrimethamine prevent
toxoplasmic encephalitis as well as 
 
P. carinii 
 
pneu-
monia.
 
9-11
 
 Primary prophylaxis against both 
 
P. carinii
F
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pneumonia and toxoplasmic encephalitis is an im-
portant component of the current treatment of pa-
tients with low CD4 counts.
 
12,13
 
Combination antiretroviral therapy reduces levels of
HIV RNA in plasma and increases CD4 counts in
most patients within a few weeks.
 
14
 
 It has also reduced
the incidence of new opportunistic infections among
patients with advanced HIV infection.
 
15,16
 
 The func-
tion of the CD4 cells gained as a result of combination
antiretroviral therapy is unclear, however. Several stud-
ies have found that the initial increase in CD4 cells
during combination antiretroviral therapy is due pre-
dominantly to the clonal expansion of memory CD4
cells — a finding that raises the question of whether
immunocompetence is truly restored.
 
17,18
 
 Converse-
ly, other groups have shown a normalization of cell-
mediated immunity against opportunistic pathogens
in functional tests within three to six months after
the initiation of therapy.
 
19
 
 In some patients, the T-cell
repertoire may reach normal levels three to six months
after combination antiretroviral therapy is begun.
 
20
 
Whether the restoration of the immune response
induced by combination antiretroviral therapy is suf-
ficient to allow prophylaxis against 
 
P. carinii 
 
pneu-
monia to be discontinued remains unclear. Current
guidelines state that the decision about whether to
initiate or continue prophylaxis should be made on
the basis of the lowest CD4 count ever measured in
the patient (nadir count).
 
21
 
 We prospectively stud-
ied the safety of discontinuing primary prophylaxis
against 
 
P. carinii 
 
pneumonia in patients receiving
combination antiretroviral therapy.
 
METHODS
 
The Swiss HIV Cohort Study
 
The Swiss HIV Cohort Study is a prospective cohort study
with ongoing enrollment of HIV-infected persons 16 years of age
or older. Enrollment in one of seven study centers (in Basel, Bern,
Geneva, Lausanne, Lugano, St. Gallen, and Zurich) is independ-
ent of the disease stage and the degree of immunosuppression.
Information is collected according to standardized criteria on
structured forms at registration and at follow-up visits, which are
scheduled at six-month intervals. The study design has been de-
scribed in detail elsewhere.
 
22
 
Inclusion and Exclusion Criteria
 
Patients receiving primary prophylaxis against 
 
P. carinii 
 
pneu-
monia and combination antiretroviral therapy, who had an in-
crease in their CD4 count to 200 cells per cubic millimeter or
higher and to at least 14 percent of total peripheral lymphocytes,
and whose counts remained above these values for at least 12
weeks, were eligible for inclusion in our study. The local ethics
committees of all seven study centers approved the study, and
written informed consent was obtained from participants. The
protocol stipulated that prophylaxis would be resumed if the CD4
count fell below at least one of the threshold values on two con-
secutive measurements. Recruitment started on June 28, 1997,
and patients were followed prospectively within the framework of
the Swiss HIV Cohort Study, except that CD4 counts were meas-
ured every three months. Study patients were instructed to con-
tact the medical center if they had any symptoms suggestive of the
presence of 
 
P. carinii
 
 pneumonia or toxoplasmic encephalitis.
 
End Points
 
A definite or presumptive diagnosis of 
 
P. carinii
 
 pneumonia
was the primary study end point. A diagnosis was considered def-
inite if 
 
P. carinii
 
 was found on microscopical analysis of induced
sputum or bronchoalveolar fluid or on histologic examination of
a lung specimen. A presumptive diagnosis was made if there was
a history of dyspnea on exertion or nonproductive cough in the
absence of evidence of bacterial pneumonia, if bronchoalveolar la-
vage was not performed, and if the patient responded to standard
treatment for 
 
P. carinii
 
 pneumonia.
The secondary end point was toxoplasmic encephalitis. A defi-
nite diagnosis was made by histologic examination of brain-biop-
sy specimens. A presumptive diagnosis was made when the fol-
lowing were present: recent onset of a focal neurologic abnormality
consistent with intracranial disease, a reduced level of conscious-
ness, or headache; evidence on computed tomography or mag-
netic resonance imaging of at least one lesion with a mass effect
or positive enhancement with contrast medium; and a response
to standard treatment for toxoplasmic encephalitis.
 
Statistical Analysis
 
All participants with at least one follow-up evaluation were in-
cluded in the analysis. The length of follow-up was measured from
the date prophylaxis against 
 
P. carinii
 
 pneumonia was stopped.
The closing date for the analysis was January 15, 1999. As of this
date, all patients’ charts were reviewed and patients were contact-
ed by phone if the treating physician had not seen them within
the previous month. If they could not be contacted, data were
censored as of the date of the last follow-up visit. Events were as-
sumed to have a Poisson distribution, and exact confidence inter-
vals were calculated for the incidence of end points. All patients
were considered to be at risk for 
 
P. carinii
 
 pneumonia, whereas
only patients who were serologically positive for IgG antibodies
to 
 
T. gondii
 
 were considered to be at risk for toxoplasmic enceph-
alitis. We used Stata software (version 5.0, Stata, College Station,
Tex.) for statistical analyses.
 
Historical Comparison Group
 
We examined the incidence of 
 
P. carinii
 
 pneumonia and toxo-
plasmic encephalitis in a historical comparison group of patients
enrolled in the Swiss HIV Cohort Study from 1990 through 1994,
before highly active antiretroviral therapy became widely available.
We stratified patients according to their CD4 count at entry
(<200, 200 to 500, or >500 cells per cubic millimeter); we then
calculated the incidence of 
 
P. carinii
 
 pneumonia and toxoplasmic
encephalitis in the first year after the date of enrollment. Patients
in whom 
 
P. carinii
 
 pneumonia or toxoplasmic encephalitis was di-
agnosed within the first month after enrollment were excluded
from the analysis, because in these patients, enrollment in the Swiss
HIV Cohort Study was probably triggered by these events.
 
RESULTS
 
Characteristics of the Patients
 
A total of 396 patients fulfilled the entry criteria,
according to the study data base. As of January 15,
1999, 279 (70.5 percent) of them had been en-
rolled. Seventeen (6.1 percent) were excluded from
the present analysis, for the following reasons: 1 re-
sumed prophylaxis because his CD4 count fell be-
low the threshold value before the first follow-up
visit, 1 resumed prophylaxis before the first follow-
up visit after an episode of bacterial pneumonia, and
15 had not completed their first follow-up visit at
the time the data were analyzed. This analysis there-
fore includes 262 (93.9 percent) of the 279 patients,
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of whom 242 (92.4 percent) were followed until the
closing date of January 15, 1999.
Data on 20 patients were censored before the
closing date of the study, for the following reasons:
9 could not be reached by telephone, 2 died (1 had
sudden death and 1 died of hepatocellular carcino-
ma); and 9 resumed prophylaxis because the CD4
count fell below the threshold value on a single meas-
urement (4 patients) or two measurements (3 pa-
tients), because of recurrent episodes of respiratory
tract infection that responded to aminopenicillin
(1 patient), or for personal reasons (1 patient).
The characteristics of the study participants are
shown in Table 1. The median age was 37 years, and
two thirds of the patients were male. Sixty-three pa-
tients (24.0 percent) were in clinical stage C, accord-
ing to the criteria of the Centers for Disease Control
and Prevention (CDC),
 
23
 
 and 113 (43.1 percent)
had had a clinical condition known to be associated
with an elevated risk of 
 
P. carinii
 
 pneumonia (recur-
rent thrush, candida esophagitis, weight loss, or fe-
ver).
 
5
 
 One hundred twenty-one (46.2 percent) were
positive for IgG antibodies to 
 
T. gondii
 
 and thus at
risk for toxoplasmic encephalitis. The median CD4
count at study entry was 325 cells per cubic milli-
meter, and the median nadir (lowest-ever-measured)
value was 110 cells per cubic millimeter (Fig. 1).
Close to 90 percent of the patients were taking com-
bination antiretroviral therapy that included at least
one protease inhibitor. Only one patient with a his-
tory of disseminated 
 
Mycobacterium avium 
 
complex
infection was receiving long-term macrolide therapy.
The 117 patients who fulfilled the entry criteria
but were not enrolled and the 17 patients who were
enrolled but were excluded from the analysis were sim-
ilar to the 262 patients included in the analysis with
regard to demographic variables; disease stage; nadir
CD4 count; history of thrush, unexplained weight
loss, or fever; and treatment history.
 
Incidence of Events during Follow-up
 
Data on incidence are summarized in Table 2. No
diagnosis of 
 
P. carinii
 
 pneumonia or toxoplasmic en-
cephalitis was recorded during follow-up. The inci-
dence of each was therefore zero. The upper 99 per-
cent Poisson confidence limits for the incidence
were 1.93 per 100 patient-years for 
 
P. carinii
 
 pneu-
monia and 4.20 per 100 patient-years for toxoplasmic
encephalitis. None of the patients had an AIDS-defin-
ing illness during follow-up. Four patients had an
event that defines CDC stage B: one patient had oral
candidiasis; one patient, thrombocytopenia; and two
patients, cervical intraepithelial dysplasia.
 
Historical Comparison Group
 
Analyses of the historical comparison group were
based on 3099 patients with a median age of 31
years, of whom 865 (27.9 percent) were female. The
 
*The stages are those of the Centers for Disease Control and Preven-
tion.
 
23
 
†Lowest CD4 counts ever measured could be either above 200 per cubic
millimeter or above 14 percent, since prophylaxis against 
 
P. carinii
 
 pneu-
monia was indicated if either of these two values was below the threshold.
‡HIV RNA was measured with either the standard Amplicor HIV-
Monitor Test (Hoffmann–LaRoche, Basel, Switzerland) or a more sensi-
tive modification of that test.
 
24
 
 Values below the threshold were defined
as 100 copies per milliliter with the standard test and equal to the limit
of detection with the more sensitive modification (2 to 40 copies per mil-
liliter).
 
T
 
ABLE
 
 1.
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 262 S
 
TUDY
 
 P
 
ATIENTS
AT
 
 B
 
ASE
 
 L
 
INE
 
 
 
AND
 
 CD4 C
 
OUNTS
 
 
 
AND VIRAL LOAD 
AT THE END OF THE STUDY.
CHARACTERISTIC VALUE
Age — yr
Median
Range
37
25–80
Sex — no. (%)
Male
Female
177 (67.6)
85 (32.4)
Risk category for transmission — no. (%)
Men who had sex with men
Heterosexual sex
Injection-drug use
Other or unknown
96 (36.6)
75 (28.6)
80 (30.5)
11 (4.2)
Clinical stage — no. (%)*
A
B
C
77 (29.4)
122 (46.6)
63 (24.0)
History of recurrent thrush, candida esophagitis,
weight loss, or fever — no. (%)
113 (43.1)
Combination antiretroviral therapy — no. (%)
Two drugs
Three or four drugs
Regimen including a protease inhibitor
35 (13.4)
227 (86.6)
232 (88.5)
IgG antibodies to Toxoplasma gondii 121 (46.2)
Prophylaxis against Pneumocystis carinii pneumonia 
— no. (%)
Trimethoprim–sulfamethoxazole
Pentamidine
Dapsone and pyrimethamine
224 (85.5)
25 (9.5)
13 (5.0)
Duration of prophylaxis — mo
Median
Range
24.6
3.3–100.3
Lowest CD4 count ever measured in patient†
Cells/mm3
Median
Range
Percentage of total peripheral lymphocytes 
Median
Range
Patients with lowest count <50/mm3 — no. (%)
110
0–240
12
0–31
57 (21.8)
CD4 count at study entry
Cells/mm3
Median
Range
Percentage of total peripheral lymphocytes
Median
Range
325
210–806
22
14–55
CD4 count at end of study
Cells/mm3
Median
Range
Percentage of total peripheral lymphocytes
Median
Range
422
122–1360
25
12–58
HIV RNA level at study entry — log10 copies/ml‡
Median
Range
2.0
0.6–5.6
HIV RNA level at end of study — log10 copies/ml‡
Median
Range
1.9
0.3–5.6
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distribution according to risk factors for transmis-
sion was as follows: 1275 (41.1 percent) had a his-
tory of injection-drug use, 988 (31.9 percent) were
men who had had sex with men, 756 (24.4 percent)
were classified as having heterosexually acquired in-
fection, and 80 (2.6 percent) had been infected
through other or unknown routes. Calculations of
incidence were based on 3099 patients and 2875 pa-
tient-years of follow-up for P. carinii pneumonia and
1089 patients with a positive IgG antibody test for
T. gondii and 1004 patient-years of follow-up for
toxoplasmic encephalitis. Data on incidence are shown
in Table 3 according to the CD4 cell count at study
entry.
DISCUSSION
We studied the incidence of P. carinii pneumonia
and toxoplasmic encephalitis in patients in whom
primary prophylaxis against P. carinii pneumonia
was discontinued after their CD4 counts increased
to at least 200 cells per cubic millimeter and 14 per-
cent of the total lymphocyte count. We included the
percentage of CD4 cells in addition to the absolute
CD4 count in our criteria because the percentage of
CD4 lymphocytes can be measured with greater re-
liability than the absolute number25 and the value of
14 percent predicts an absolute count of 200 cells per
cubic millimeter in a validated model.26 CD4 counts
were required to be above the defined threshold for
at least 12 weeks before prophylaxis was stopped so
as to achieve a reasonable margin of safety in deter-
mining that there had been a sustained increase. We
could thus be confident that prophylaxis was being
stopped only in patients with CD4 cell counts at
levels that are known to confer protection against
P. carinii pneumonia and toxoplasmosis in HIV-
infected patients who are not treated with combina-
tion antiretroviral therapy.
In this population, the incidence of P. carinii
pneumonia during the first year after prophylaxis was
discontinued was zero, with an upper 99 percent
confidence limit of less than 2 cases per 100 patient-
years. The number of patients at risk for toxoplasmic
encephalitis was lower, so that the estimate of the in-
cidence of this condition is less precise, but the rate
in the first year was almost certainly below 5 cases
per 100 patient-years.
The estimated risk of P. carinii pneumonia or tox-
oplasmic encephalitis in our patients was similar to
the risk among patients with CD4 counts below
200 cells per cubic millimeter who continue to take
trimethoprim–sulfamethoxazole in the setting of a
controlled clinical trial,7 and it was smaller than the
risk of P. carinii pneumonia in patients who receive
inhaled pentamidine or dapsone, with or without
pyrimethamine, in clinical trials.6,9,10,27
Our results suggest that combination antiretrovi-
ral therapy induces a clinically significant restoration
Figure 1. CD4 Counts among Patients in Whom Prophylaxis
against Pneumocystis carinii Pneumonia Was Stopped.
Shown are the lowest CD4 count ever measured in each pa-
tient, the count at study entry, and the count at the end of the
study. The horizontal lines indicate the 25th, 50th, and 75th per-
centiles, and the I bars the 10th and 90th percentiles.
0
700
100
200
300
400
500
600
At StudyE
Entry
LowestE
Ever
At EndE
of Study
C
D
4 
C
o
u
n
t 
(c
el
ls
/m
m
3 )
*One-sided Poisson confidence limits are shown.
TABLE 2. FOLLOW-UP AND INCIDENCE 
OF PNEUMOCYSTIS CARINII PNEUMONIA 
AND TOXOPLASMIC ENCEPHALITIS 
AMONG 262 PATIENTS IN WHOM PROPHYLAXIS 
WAS DISCONTINUED.
VARIABLE VALUE
P. carinii pneumonia
No. of patients at risk 262
Length of follow-up — mo
Median
Range
11.3
3.0–18.8
Total follow-up — yr 238.2
Patients with »1 yr of follow-up — no. (%) 106 (40.5)
Incidence (per 100 patient-yr)
Upper 95% confidence limit*
Upper 99% confidence limit*
0
1.26
1.93
Toxoplasmic encephalitis
No. of patients at risk 121
Length of follow-up — mo
Median
Range
11.0
3.3–18.8
Total follow-up — yr 109.7
Patients with »1 yr of follow-up — no. (%) 49 (40.5)
Incidence (per 100 patient-yr)
Upper 95% confidence limit*
Upper 99% confidence limit*
0
2.73
4.20
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of immunity against P. carinii. Our study subjects
were at substantial risk for P. carinii pneumonia be-
fore the increase in their CD4 counts. Indeed, half
of our patients had CD4 counts below 110 per cubic
millimeter before they began combination antiretro-
viral therapy. This value is identical to the median
CD4 count in a previous trial conducted within the
framework of the Swiss HIV Cohort Study, in which
the incidence of P. carinii pneumonia was 27 per 100
patient-years in the absence of combination antiret-
roviral therapy and of prophylaxis against P. carinii
pneumonia.6 Clearly, many cases of P. carinii pneu-
monia would have been expected in the present study
population had immune reconstitution not been
successful.
A historical comparison with patients whose CD4
cell counts never dropped below 200 cells per cubic
millimeter and who were not treated with combina-
tion antiretroviral therapy provides further evidence
of a genuine restoration of immune function in our
study group. The median CD4 count at entry in our
study was similar to the CD4 count among patients
enrolled with CD4 counts of 200 to 500 cells per
cubic millimeter during 1990 to 1994, before pro-
tease inhibitors became widely available. A compar-
ison of estimates of incidence and confidence inter-
vals for this historical group with the results of our
present study group indicates that the estimates are
similar.
Our results are in line with those of several ongo-
ing studies that were recently presented in abstracts
and preliminary reports.28 Schneider and colleagues
observed no events after primary or secondary pro-
phylaxis was stopped, but their study was small and
their data did not exclude the possibility of a sub-
stantial risk of P. carinii pneumonia.29 We did not
study the risk of stopping secondary prophylaxis. In-
terestingly, preliminary results are also encouraging
in studies in which anticytomegalovirus treatment
was stopped in patients with cytomegalovirus retini-
tis who had a good response to highly active antiret-
roviral therapy.30,31 Stopping secondary prophylaxis
against P. carinii pneumonia or toxoplasmic enceph-
alitis may well be safe in such patients, but further
data are needed before this approach can be recom-
mended.
The median follow-up in this study was more than
11 months, and more than 100 patients were followed
for at least 1 year. However, our study cannot exclude
with certainty the possibility of an increase in the
risk of P. carinii pneumonia and toxoplasmic enceph-
alitis one year after prophylaxis stopped. Immune
function increases with time after the successful ini-
tiation of combination antiretroviral therapy.17 More-
over, the incidence of opportunistic infections remains
high during the first months of treatment but de-
clines thereafter.32 An increase in the risk of P. carinii
pneumonia is therefore unlikely if CD4 counts are
maintained at safe levels. If the failure of therapy
leads to a decline in CD4 counts to levels below 200
cells per cubic millimeter, therefore, prophylaxis should
be reintroduced. We restarted prophylaxis for this
reason in only seven patients.
This was an uncontrolled, observational study.
The possibility of bias due to the selection of pa-
tients at low risk must be considered, but such bias
is unlikely. The Swiss HIV Cohort Study includes
about 70 percent of all patients with advanced dis-
ease in the country.33 A large proportion of the eli-
gible patients were included in our analysis, and
those who were not included had characteristics
similar to those of the study patients. We considered
performing a randomized, controlled trial but con-
cluded that it would not be possible to recruit the
large number of patients required to show equiva-
lence between the group in which prophylaxis was
stopped and that in which it was continued.
In conclusion, we have shown that it is safe to
stop primary prophylaxis against P. carinii pneumo-
nia in patients who have responded to combination
antiretroviral therapy with an increase in the CD4
count to at least 200 cells per cubic millimeter and
14 percent of total peripheral lymphocytes that has
been sustained for at least 12 weeks. The study par-
ticipants in this large community-based cohort in-
cluded men and women at all clinical stages of HIV
disease, who had acquired HIV infection through
both sexual and parenteral routes. The results should
therefore be applicable to patients seen in daily clin-
ical practice, if our entry and follow-up criteria are
followed.
*The historical comparison group was made up of patients enrolled in
the Swiss HIV Cohort Study in 1990 through 1994.
TABLE 3. INCIDENCE OF PNEUMOCYSTIS CARINII PNEUMONIA 
AND TOXOPLASMIC ENCEPHALITIS DURING THE FIRST YEAR 
AFTER STUDY ENTRY IN THE HISTORICAL COMPARISON GROUP 
OF 3099 PATIENTS, ACCORDING TO BASE-LINE CD4 COUNT.*
VARIABLE CD4 COUNT AT STUDY ENTRY
<200 
CELLS/mm3
200–500 
CELLS/mm3
>500
CELLS/mm3
Pneumocystis carinii pneumonia
No. of patients at risk 918 1277 904
Median CD4 count (cells/mm3) 100 330 680
Incidence (per 100 patient-yr)
95% confidence interval
99% confidence interval
6.1
4.5–8.1
4.1–8.8
1.1
0.6–1.8
0.5–2.1
0.1
0.001–0.6
0.00001–0.8
Toxoplasmic encephalitis
No. of patients at risk 363 437 289
Median CD4 count (cells/mm3) 100 326 670
Incidence (per 100 patient-yr)
95% confidence interval
99% confidence interval
15.9
11.7–21.0
10.6–22.7
1.2
0.4–2.8
0.3–3.4
0.4
0.001–2.0
0.001–2.6
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APPENDIX
The members of the Swiss HIV Cohort Study are as follows: M. Batte-
gay (cochair of the Scientific Board), E. Bernasconi, P. Bürgisser, M. Egger,
P. Erb, W. Fierz, M. Flepp (chair of the Clinics Group), P. Francioli (pres-
ident of the study), H. Furrer, P. Grob, B. Hirschel (cochair of the Scien-
tific Board), B. Ledergerber, R. Malinverni, L. Matter (chair of the Labo-
ratories Group), A. Meynard, M. Opravil, F. Paccaud, G. Pantaleo, L.
Perrin, W. Pichler, J.-C. Piffaretti, M. Rickenbach (head of the data center),
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